Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Common Equity (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Common Equity for 7 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 18.5% year-over-year to $1.7 billion, compared with a TTM value of $1.7 billion through Dec 2025, up 18.5%, and an annual FY2025 reading of $1.7 billion, up 18.5% over the prior year.
  • Common Equity was $1.7 billion for Q4 2025 at Avidity Biosciences, down from $1.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.9 billion in Q3 2025 and bottomed at $264.5 million in Q2 2021.
  • Average Common Equity over 5 years is $812.2 million, with a median of $559.0 million recorded in 2023.
  • Peak annual rise in Common Equity hit 503.19% in 2021, while the deepest fall reached 19.93% in 2021.
  • Year by year, Common Equity stood at $381.4 million in 2021, then skyrocketed by 51.55% to $578.1 million in 2022, then decreased by 13.37% to $500.8 million in 2023, then surged by 184.56% to $1.4 billion in 2024, then increased by 18.5% to $1.7 billion in 2025.
  • Business Quant data shows Common Equity for RNA at $1.7 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.2 billion in Q2 2025.